IL314798A - Prostate cancer treatment methods - Google Patents

Prostate cancer treatment methods

Info

Publication number
IL314798A
IL314798A IL314798A IL31479824A IL314798A IL 314798 A IL314798 A IL 314798A IL 314798 A IL314798 A IL 314798A IL 31479824 A IL31479824 A IL 31479824A IL 314798 A IL314798 A IL 314798A
Authority
IL
Israel
Prior art keywords
methods
prostate cancer
treating prostate
treating
cancer
Prior art date
Application number
IL314798A
Other languages
English (en)
Hebrew (he)
Inventor
Jinyu Kang
Original Assignee
Astrazeneca Ab
Jinyu Kang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Jinyu Kang filed Critical Astrazeneca Ab
Publication of IL314798A publication Critical patent/IL314798A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL314798A 2022-02-15 2023-02-14 Prostate cancer treatment methods IL314798A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263268026P 2022-02-15 2022-02-15
PCT/EP2023/053555 WO2023156357A1 (en) 2022-02-15 2023-02-14 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
IL314798A true IL314798A (en) 2024-10-01

Family

ID=85283519

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314798A IL314798A (en) 2022-02-15 2023-02-14 Prostate cancer treatment methods

Country Status (11)

Country Link
US (1) US20250134887A1 (https=)
EP (1) EP4479053A1 (https=)
JP (1) JP2025505041A (https=)
KR (1) KR20240148418A (https=)
CN (1) CN118829430A (https=)
AU (1) AU2023220646A1 (https=)
CA (1) CA3250763A1 (https=)
IL (1) IL314798A (https=)
MX (1) MX2024009923A (https=)
TW (1) TW202400267A (https=)
WO (1) WO2023156357A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer

Also Published As

Publication number Publication date
US20250134887A1 (en) 2025-05-01
EP4479053A1 (en) 2024-12-25
WO2023156357A1 (en) 2023-08-24
TW202400267A (zh) 2024-01-01
KR20240148418A (ko) 2024-10-11
CN118829430A (zh) 2024-10-22
MX2024009923A (es) 2024-08-22
JP2025505041A (ja) 2025-02-19
CA3250763A1 (en) 2023-08-24
AU2023220646A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
IL320743A (en) A method for treating prostate cancer
IL320332A (en) Cancer treatment methods
IL308766A (en) Compositions and methods for treating prostate cancer
EP4111202A4 (en) CANCER TREATMENT METHODS
IL307381A (en) Diagnostic methods of prostate cancer
IL305965A (en) ARENAVIRUSES USED IN PROSTATE CANCER TREATMENTS
IL325326A (en) Cancer treatment method with indulin inhibitors of kif18a
IL320962A (en) Methods for treating advanced solid tumors
IL314798A (en) Prostate cancer treatment methods
IL325454A (en) Prostate cancer treatment method
IL272390A (en) Cancer treatment methods
IL312155A (en) A method for treating cancer
IL314687A (en) Cancer treatment
IL326327A (en) Prostate cancer treatment
HK40122526A (en) Methods of treating prostate cancer
IL315569A (en) Cancer treatment methods
HK40087831A (en) Methods of treating prostate cancer
IL307556A (en) Cancer treatment methods using antibodies against TIGIT
CA3274501A1 (en) Method of treating prostate cancer
IL312332A (en) Cancer treatment methods
IL320448A (en) Methods of treating cancer using sutorsiv
IL326216A (en) Combination therapy for prostate cancer
CA3265149A1 (en) METHODS OF TREATMENT OF PROSTATE CANCER USING EXICORILANT AND ENZALUTAMIDE
CA3300083A1 (en) Treatment of prostate cancer
IL308684A (en) Methods of treating breast cancer